Ga direct naar de inhoud

Ga direct naar de navigatie

Uitgave van

Archief voor de categorie ‘Overig’

Zo maak je een contentstrategie die omzet oplevert

Bedrijven geven miljoenen euro’s uit aan contentmarketing. Toch hebben de meeste bedrijven geen flauw idee wat het ze oplevert. Of nog erger… het interesseert ze niet. Het fenomeen contentmarketing is zo gehypet dat het grotendeel van de bedrijven geen seconde stilstaat bij wat het doel is van contentmarketing.

Bron: Frankwatching.nl Meer lezen »

GDPR: de gevolgen voor tracking en analytics

Op 25 mei 2018 treedt de nieuwe privacywetgeving in werking. In de General Data Protection Regulation (GDPR) – oftewel de Algemene Verordening Gegevensbescherming (AVG) – staan nieuwe, herziene richtlijnen voor het verzamelen van data, in het leven geroepen om de privacy van de burger beter te waarborgen.  

Bron: marketingfacts.nl Meer lezen »

Asking the right questions: Measuring the impact of pharmacovigilance

Are our pharmacovigilance measures as effective as we think? And why is it important to answer that question, especially now? Matt Fellows investigates the projects underway to ensure we’re headed in the right direction.

Bron: Pharmafile Meer lezen »

FDA expands Janssen’s Stelara to cover adolescent psoriasis patients

Janssen has announced that the FDA has approved an expanded indication for its psoriasis therapy Stelara (ustekinumab) for the treatment of moderate to severe plaque forms of the disease in adolescent patients aged 12 or over who are candidates for phototherapy or systemic therapy.

Bron: Pharmafile Meer lezen »

Pfizer reviewing strategic alternatives for Consumer Healthcare business

Pfizer Inc. is reviewing strategic alternatives for its Consumer Healthcare business. A range of options will be considered, including a full or partial separation of the Consumer Healthcare business from Pfizer through a spin-off, sale or other transaction, and Pfizer may ultimately determine to retain the business. This announcement is part of Pfizer’s continuing efforts […]

Bron: World Pharma News Meer lezen »

AstraZeneca’s Tagrisso secures breakthrough therapy designation in first-line NSCLC

AstraZeneca has announced that its immunotherapy Tagrisso (osimertinib) has been awarded Breakthrough Therapy Designation by the FDA for the first-line treatment of patients with metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).

Bron: Pharmafile Meer lezen »

Mylan and Biocon Neulasta biosimilar knocked back by FDA

Mylan and Biocon’s biosimilar version of Amgen’s blockbuster, Neulasta (pegfilgrastim), will have to wait a bit longer before getting the nod from the FDA, after receiving a CRL related manufacturing plant issues. In reality, it shouldn’t be more than a hiccup for the partnership, with Biocon stating that it shouldn’t change the commercialisation timeframe.

Bron: Pharmafile Meer lezen »

3 ‘seo-factoren’ die eigenlijk helemaal niet bestaan

SEO, zoekmachine-optimalisatie, is een lastig en soms nogal een abstract onderwerp. Er gaan veel verhalen over rond. Sommige terecht, andere zijn simpelweg verzonnen. De moeilijkheid zit hem in het feit dat seo nu eenmaal voor een groot deel abstract ís.

Bron: marketingfacts.nl Meer lezen »

BMS agrees deal on Opdivo availability through Cancer Drugs Fund for head and neck cancer

Thanks to successful negotiation of a managed access agreement, NICE has announced its recommendation of Bristol-Myers Squibb’s Opdivo (nivolumab) for inclusion in the Cancer Drugs Fund (CDF) for the treatment of squamous cell carcinoma of the head and neck which has metastasized in patients who have not responded to chemotherapy within six months.

Bron: Pharmafile Meer lezen »

Breakthrough study could revolutionise MS treatment

The results of a study from the University of California, San Francisco will be welcomed with a certain excitement from all quarters, given that it seems to show the repair of myelin damaged by multiple sclerosis (MS) and, to add to the news, is achieved through the use of a generic allergy medication.

Bron: Pharmafile Meer lezen »

« Oudere artikelen |